Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Definium Therapeutics, Inc.(DFTX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for DFTX
11/06/2026: DFTX (3-star) is currently NOT-A-BUY. Pass it for now.
Definium Therapeutics is a clinical-stage biotechnology company focused on developing novel treatments for psychiatric and neurological disorders. Its primary value proposition centers on the progression of lead candidate DT120, which is in Phase 3 trials, through a data-driven clinical model. While the company has gained visibility and investor interest through successful trial milestones, it remains pre-revenue and faces significant risks, including high cash burn and stiff competition from large-cap pharmaceutical firms. This stock is best suited for growth-oriented investors with a high tolerance for volatility who are comfortable with the inherent risks of drug development. Investors should prioritize monitoring upcoming clinical trial readouts and potential regulatory updates.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers high-risk, high-reward potential based on clinical pipeline development. |
| Momentum investor | Strong fit while signal remains positive | The stock often reacts strongly to clinical milestone news and regulatory progress. |
| Value investor | Weak fit | The company lacks current earnings and relies on clinical speculation rather than established cash flows. |
| Dividend investor | Weak fit | No dividend is paid or expected in the foreseeable future. |
| Low-risk investor | Weak fit | High volatility associated with clinical-stage biotech stocks makes this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage stocks are highly sensitive to study results and regulatory news. |
| Valuation risk | High | Valuations are driven by speculative future successes rather than tangible current revenue. |
| Competition risk (large pharma) | High | Established players have significantly more resources for marketing and lobbying. |
| Business quality | Medium | The company is transitioning from research to clinical validation, requiring strong execution. |
| Dividend income | Low / none | Investors receive zero income from this position. |
| Execution risk | Medium / high | Successful trial execution is the primary driver of shareholder value. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 318.94% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/06/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.47B USD | Price to earnings Ratio - | 1Y Target Price 72.56 |
Price to earnings Ratio - | 1Y Target Price 72.56 | ||
Volume (30-day avg) 2.0M shares | Beta 2.21 | 52 Weeks Range 10.46 - 49.70 | Updated Date 11/08/2026 |
52 Weeks Range 10.46 - 49.70 | Updated Date 11/08/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.43 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Drug Development | Clinical trial assets DT120 and DT402. | The company currently makes no revenue and operates by spending cash to develop drugs. |
| Digital Therapeutics | Digital health platforms acquired from HealthMode. | This segment supports drug development efficiency rather than direct sales. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3.42B | Price to Sales(TTM) - |
Enterprise Value 3.42B | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 134.37M | Shares Floating 125.52M |
Shares Outstanding 134.37M | Shares Floating 125.52M | ||
Percent Insiders 2.57 | Percent Institutions 89.2 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.